The colorectal cancer market in North America is expected to grow from US$ 8,559.27 million in 2022 to US$ 11,198.11 million by 2028; it is estimated to grow at a CAGR of 3.4% from 2022 to 2028.
Colorectal cancer is one of the most commonly found lethal cancers in individuals with the combined influence of genetic and environmental factors. A significant population in North America is diagnosed with colorectal cancer. According to the Centers for Disease Control and Prevention (CDC) and the American Cancer Society, an estimated 1.93 million adults in the US were diagnosed with colon and rectum cancer, and 53,200 deaths were caused by colorectal cancer in 2020. These statistics showcase increased demand for advanced cancer diagnostics and therapeutics in the region. Thus, the rising prevalence of colorectal cancer and the rising number of patients diagnosed with the disease are driving the growth of the North America colorectal cancer market.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the North America colorectal cancer market at a substantial CAGR during the forecast period.
North America Colorectal Cancer Market Revenue and Forecast to 2028 (US$ Million)
North America Colorectal Cancer Market Segmentation
The North America colorectal cancer market is segmented into modality, end user, and country. Based on modality, the North America colorectal cancer market is segmented into diagnosis type, therapy type, and imaging type. In 2022, the diagnosis type segment held the largest market share and is expected to register the highest CAGR during the forecast period. Based on end user, the North America colorectal cancer market is bifurcated into hospitals and diagnostic & research laboratories. In 2022, the hospitals segment held a larger market share. Based on country, the North America colorectal cancer market is segmented into the US, Canada, and Mexico. The US held the largest market share in 2022.
Abbott, Amgen Inc., Bruker Corporation, Clinical Genomics Technologies Pty Ltd., Epigenomics AG, F. Hoffmann-La Roche AG, Quest Diagnostics, and VolitionRx Limited are among the leading companies operating in the North America colorectal cancer market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 8,559.27 Million |
| Market Size by 2028 | US$ 11,198.11 Million |
| CAGR (2022 - 2028) | 3.4% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2028 |
| Segments Covered |
By Modality
|
| Regions and Countries Covered |
North America
|
| Market leaders and key company profiles |
|
The North America Colorectal Cancer Market is valued at US$ 8,559.27 Million in 2022, it is projected to reach US$ 11,198.11 Million by 2028.
As per our report North America Colorectal Cancer Market, the market size is valued at US$ 8,559.27 Million in 2022, projecting it to reach US$ 11,198.11 Million by 2028. This translates to a CAGR of approximately 3.4% during the forecast period.
The North America Colorectal Cancer Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Colorectal Cancer Market report:
The North America Colorectal Cancer Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The North America Colorectal Cancer Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the North America Colorectal Cancer Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For North America Colorectal Cancer Market
